Understanding and treatment of cutaneous graft-versus-host-disease.

Humans Quality of Life Skin Diseases / etiology Graft vs Host Disease / diagnosis Skin Bone Marrow Transplantation / adverse effects Hematopoietic Stem Cell Transplantation / adverse effects

Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 02 07 2023
accepted: 08 09 2023
revised: 28 08 2023
medline: 4 12 2023
pubmed: 21 9 2023
entrez: 20 9 2023
Statut: ppublish

Résumé

The skin is the outermost mechanical barrier where dynamic immune reactions take place and is the most commonly affected site in both acute and chronic graft-versus-host disease (GVHD). If not properly treated, pain and pruritis resulting from cutaneous GVHD can increase the risk of secondary infection due to erosions, ulcerations, and damage of underlying tissues. Furthermore, resulting disfiguration can cause distress and significantly impact patients' quality of life. Thus, a deeper understanding of skin-specific findings of GVHD is needed. This review will highlight some promising results of recent pre-clinical studies on the pathophysiology of skin GVHD and summarize the diagnostic and staging/grading procedures according to the clinical manifestations of skin GVHD. In addition, we will summarize outcomes of various GVHD treatments, including skin-specific response rates.

Identifiants

DOI: 10.1038/s41409-023-02109-x PMID: 37730800
pubmed: 37730800
doi: 10.1038/s41409-023-02109-x
pii: 10.1038/s41409-023-02109-x
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1298-1313

Subventions

Organisme : American Cancer Society (American Cancer Society, Inc.)
ID : CSDG-18-198-01-LIB

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7:e157–e67.
pubmed: 32004485 doi: 10.1016/S2352-3026(19)30256-X
Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340–52.
pubmed: 17438575 doi: 10.1038/nri2000
Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48.
pubmed: 37342922 doi: 10.1056/NEJMoa2215943
Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–15.
pubmed: 25398933 pmcid: 4304105 doi: 10.1182/blood-2014-08-551994
Hillen U, Hausermann P, Massi D, Janin A, Wolff D, Lawitschka A, et al. Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft-versus-host disease. J Eur Acad Dermatol Venereol. 2015;29:948–54.
pubmed: 25265987 doi: 10.1111/jdv.12737
Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–5.
pubmed: 11951032 doi: 10.1126/science.1071059
Santos ESP, Bennett CL, Chakraverty R. Unraveling the mechanisms of cutaneous graft-versus-host disease. Front Immunol. 2018;9:963.
doi: 10.3389/fimmu.2018.00963
Gooptu M, Koreth J. Translational and clinical advances in acute graft-versus-host disease. Haematologica. 2020;105:2550–60.
pubmed: 33054103 pmcid: 7604566 doi: 10.3324/haematol.2019.240309
Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377:2167–79.
pubmed: 29171820 pmcid: 6034180 doi: 10.1056/NEJMra1609337
Zeiser R. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2019;187:563–72.
pubmed: 31588560 doi: 10.1111/bjh.16190
Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17:187–94.
pubmed: 14556773 doi: 10.1016/S0268-960X(03)00009-2
Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML, et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120:4093–103.
pubmed: 22972985 pmcid: 3496960 doi: 10.1182/blood-2012-01-403196
Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Investig. 2000;105:1289–98.
pubmed: 10792004 pmcid: 315439 doi: 10.1172/JCI7894
Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood. 2009;113:1365–74.
pubmed: 18957685 pmcid: 2637199 doi: 10.1182/blood-2008-06-162420
Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565–79.
pubmed: 29281578 doi: 10.1056/NEJMra1703472
Martires KJ, Baird K, Citrin DE, Hakim FT, Pavletic SZ, Cowen EW. Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses. Arch Dermatol. 2011;147:1081–6.
pubmed: 21931046 pmcid: 7384357 doi: 10.1001/archdermatol.2011.226
Flynn R, Paz K, Du J, Reichenbach DK, Taylor PA, Panoskaltsis-Mortari A, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127:2144–54.
pubmed: 26983850 pmcid: 4850869 doi: 10.1182/blood-2015-10-678706
Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111:16814–9.
pubmed: 25385601 pmcid: 4250132 doi: 10.1073/pnas.1414189111
Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144–50.
pubmed: 12925844 doi: 10.1038/nm915
Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007;110:3804–13.
pubmed: 17693581 pmcid: 2077325 doi: 10.1182/blood-2007-05-091074
Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106:2903–11.
pubmed: 15972448 pmcid: 1895303 doi: 10.1182/blood-2005-03-1257
Caramalho I, Nunes-Cabaco H, Foxall RB, Sousa AE. Regulatory T-cell development in the human thymus. Front Immunol. 2015;6:395.
pubmed: 26284077 pmcid: 4522873 doi: 10.3389/fimmu.2015.00395
Hoffmann P, Edinger M. CD4+CD25+ regulatory T cells and graft-versus-host disease. Semin Hematol. 2006;43:62–9.
pubmed: 16412790 doi: 10.1053/j.seminhematol.2005.09.006
Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123:3988–98.
pubmed: 24820310 pmcid: 4064335 doi: 10.1182/blood-2014-03-562231
Jin H, Ni X, Deng R, Song Q, Young J, Cassady K, et al. Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood. 2016;127:2249–60.
pubmed: 26884373 pmcid: 4859199 doi: 10.1182/blood-2015-09-668145
MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129:13–21.
pubmed: 27821504 pmcid: 5216261 doi: 10.1182/blood-2016-06-686618
Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110:237–41.
pubmed: 17363728 doi: 10.1182/blood-2007-01-071043
Yamakawa T, Ohigashi H, Hashimoto D, Hayase E, Takahashi S, Miyazaki M, et al. Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. Blood. 2018;131:1476–85.
pubmed: 29363541 doi: 10.1182/blood-2017-04-779934
Alexander KA, Flynn R, Lineburg KE, Kuns RD, Teal BE, Olver SD, et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest. 2014;124:4266–80.
pubmed: 25157821 pmcid: 4191032 doi: 10.1172/JCI75935
Taylor DK, Mittereder N, Kuta E, Delaney T, Burwell T, Dacosta K, et al. T follicular helper-like cells contribute to skin fibrosis. Sci Transl Med. 2018;10.
Bucher C, Koch L, Vogtenhuber C, Goren E, Munger M, Panoskaltsis-Mortari A, et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood. 2009;114:5375–84.
pubmed: 19843883 pmcid: 2796140 doi: 10.1182/blood-2009-05-221135
Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67:103–17.
pubmed: 25395505 pmcid: 4279074 doi: 10.1124/pr.114.009381
Zanin-Zhorov A, Blazar BR. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease. Clin Immunol. 2021;230:108823.
pubmed: 34400321 pmcid: 8456981 doi: 10.1016/j.clim.2021.108823
Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute graft versus host disease: a comprehensive review. Anticancer Res. 2017;37:1547–55.
pubmed: 28373413 doi: 10.21873/anticanres.11483
Hofmeister CC, Quinn A, Cooke KR, Stiff P, Nickoloff B, Ferrara JL. Graft-versus-host disease of the skin: life and death on the epidermal edge. Biol Blood Marrow Transplant. 2004;10:366–72.
pubmed: 15148490 doi: 10.1016/j.bbmt.2004.03.003
Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:397–406.
pubmed: 3322360 doi: 10.1111/j.1365-2141.1987.tb06160.x
Gupta A, Punatar S, Gawande J, Mathew L, Bagal B, Kannan S, et al. Risk factors, pattern and clinical outcome of acute graft versus host disease in acute leukemia patients undergoing allogeneic stem cell transplant. Indian J Hematol Blood Transfus. 2015;31:404–12.
pubmed: 26306063 pmcid: 4542763 doi: 10.1007/s12288-014-0499-5
Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307.
pubmed: 22010102 pmcid: 3251233 doi: 10.1182/blood-2011-06-364265
Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, et al. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. Biol Blood Marrow Transplant. 2016;22:134–40.
pubmed: 26365153 doi: 10.1016/j.bbmt.2015.09.008
Lee SE, Cho BS, Kim JH, Yoon JH, Shin SH, Yahng SA, et al. Risk and prognostic factors for acute GVHD based on NIH consensus criteria. Bone Marrow Transplant. 2013;48:587–92.
pubmed: 23000645 doi: 10.1038/bmt.2012.187
Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80:1838–45.
pubmed: 1391947 doi: 10.1182/blood.V80.7.1838.1838
Ilyas M, Colegio OR, Kaplan B, Sharma A. Cutaneous toxicities from transplantation-related medications. Am J Transplant. 2017;17:2782–9.
pubmed: 28452165 doi: 10.1111/ajt.14337
Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol. 2018;19:33–50.
pubmed: 28656563 doi: 10.1007/s40257-017-0306-9
Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity reactions. J Am Acad Dermatol. 2011;65:726–32.
pubmed: 21641677 doi: 10.1016/j.jaad.2010.07.042
Hunjan MK, Nowsheen S, Ramos-Rodriguez AJ, Hashmi SK, Bridges AG, Lehman JS, et al. Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2019;12:19–25.
pubmed: 30248313 doi: 10.1016/j.hemonc.2018.09.001
Matsushita T, Hasegawa M, Shirasaki F, Fujimoto M, Yamazaki H, Sato S, et al. A case of acute cutaneous graft-versus-host disease mimicking psoriasis vulgaris. Dermatology. 2008;216:64–7.
pubmed: 18032902 doi: 10.1159/000109361
Surjana D, Robertson I, Kennedy G, James D, Weedon D. Acute cutaneous graft-versus-host disease resembling type II (atypical adult) pityriasis rubra pilaris. Australas J Dermatol. 2015;56:e21–3.
pubmed: 25688705 doi: 10.1111/ajd.12108
Huang J, Pol-Rodriguez M, Silvers D, Garzon MC. Acquired ichthyosis as a manifestation of acute cutaneous graft-versus-host disease. Pediatr Dermatol. 2007;24:49–52.
pubmed: 17300650 doi: 10.1111/j.1525-1470.2007.00333.x
Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2:e21–9.
pubmed: 26687425 pmcid: 4340092 doi: 10.1016/S2352-3026(14)00035-0
Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109:2751–8.
pubmed: 17138825 doi: 10.1182/blood-2006-07-034348
Hong KT, Kang HJ, Kim NH, Kim MS, Lee JW, Kim H, et al. Peri-engraftment syndrome in allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48:523–8.
pubmed: 23000648 doi: 10.1038/bmt.2012.171
Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:469–75.
pubmed: 25581406 doi: 10.1038/bmt.2014.296
Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893–8.
pubmed: 11436099 doi: 10.1038/sj.bmt.1703015
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22:4–10.
pubmed: 26386318 doi: 10.1016/j.bbmt.2015.09.001
Hausermann P, Walter RB, Halter J, Biedermann BC, Tichelli A, Itin P, et al. Cutaneous graft-versus-host disease: a guide for the dermatologist. Dermatology. 2008;216:287–304.
pubmed: 18230976 doi: 10.1159/000113941
Lehman JS, Dasari S, Damodaran SS, Li M, Hashmi SK, el-Azhary RA, et al. Differentiation of acute graft-versus-host disease from drug reaction in skin by a novel tissue-based biomarker assay. 2023. Preprint at https://assets.researchsquare.com/files/rs-2481845/v1/4325b9da-21cc-4b24-ab0f-4dce6f29b0e9.pdf?c=1673971615 .
Lehman JS, Dasari S, Damodaran SS, El-Azhary RA, Gibson LE, Hashmi SK, et al. Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin. Clin Exp Dermatol. 2019;44:e81–8.
pubmed: 30280423 doi: 10.1111/ced.13759
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
pubmed: 4153799 doi: 10.1097/00007890-197410000-00001
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.
Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–64.
pubmed: 9217189 doi: 10.1046/j.1365-2141.1997.1112925.x
Moore RA, Waheed A, Burns B, Rule of nines. Treasure Island (FL): StatPearls; 2022.
Tso S, Satchwell F, Moiz H, Hari T, Dhariwal S, Barlow R, et al. Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation and pathogenesis. Clin Exp Dermatol. 2021;46:1001–10.
pubmed: 33639006 doi: 10.1111/ced.14625
Inamadar AC, Ragunatha S. The rash that becomes an erythroderma. Clin Dermatol. 2019;37:88–98.
pubmed: 30981298 doi: 10.1016/j.clindermatol.2018.12.002
Miyashiro D, Sanches JA. Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. Sci Rep. 2020;10:9774.
pubmed: 32555205 pmcid: 7300014 doi: 10.1038/s41598-020-66040-7
Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459–64.
pubmed: 2350582 doi: 10.1182/blood.V75.12.2459.2459
Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22:755–61.
pubmed: 9827972 doi: 10.1038/sj.bmt.1701423
Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25:94–9.
pubmed: 30195074 doi: 10.1016/j.bbmt.2018.08.028
Lv M, Zhang X, Xu L, Wang Y, Yan C, Chen H, et al. Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. Front Med. 2019;13:667–79.
pubmed: 31512033 doi: 10.1007/s11684-019-0702-z
Ochs LA, Miller WJ, Filipovich AH, Haake RJ, McGlave PB, Blazar BR, et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant. 1994;13:455–60.
pubmed: 8019471
Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001;98:1695–700.
pubmed: 11535499 doi: 10.1182/blood.V98.6.1695
Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood. 2005;105:548–51.
pubmed: 15367429 doi: 10.1182/blood-2004-03-1000
Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:674–82.
pubmed: 12523580 doi: 10.1053/bbmt.2002.v8.abbmt080674
Yang F, Lu D, Hu Y, Huang X, Huang H, Chen J, et al. Risk factors for graft-versus-host disease after transplantation of hematopoietic stem cells from unrelated donors in the china marrow donor program. Ann Transplant. 2017;22:384–401.
pubmed: 28652564 pmcid: 6248289 doi: 10.12659/AOT.902805
Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 2012;120:2545–52.
pubmed: 22773386 pmcid: 3460679 doi: 10.1182/blood-2012-04-424135
Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117:3214–9.
pubmed: 21263156 pmcid: 3062319 doi: 10.1182/blood-2010-08-302109
Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol Blood Marrow Transplant. 2016;22:1781–91.
pubmed: 27343720 doi: 10.1016/j.bbmt.2016.06.020
Wojnar J, Giebel S, Holowiecka-Goral A, Krawczyk-Kulis M, Markiewicz M, Wozniczka K, et al. The incidence and risk factors for chronic graft-versus-host-disease. Ann Transplant. 2006;11:14–20.
pubmed: 17494284
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389–401.e1.
pubmed: 25529383 doi: 10.1016/j.bbmt.2014.12.001
Link-Rachner CS, Sockel K, Schuetz C. Established and emerging treatments of skin GvHD. Front Immunol. 2022;13:838494.
pubmed: 35185931 pmcid: 8847139 doi: 10.3389/fimmu.2022.838494
Hymes SR, Turner ML, Champlin RE, Couriel DR. Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12:1101–13.
pubmed: 17085303 doi: 10.1016/j.bbmt.2006.08.043
Wang JY, Tabata MM, Pugliese S, Phillips D, Kim J, Weng WK, et al. Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients. Clin Case Rep. 2019;7:2491–4.
pubmed: 31893086 pmcid: 6935619 doi: 10.1002/ccr3.2458
Penas PF, Jones-Caballero M, Aragues M, Fernandez-Herrera J, Fraga J, Garcia-Diez A. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol. 2002;138:924–34.
pubmed: 12071820 doi: 10.1001/archderm.138.7.924
Schaffer JV, McNiff JM, Seropian S, Cooper DL, Bolognia JL. Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol. 2005;53:591–601.
pubmed: 16198778 doi: 10.1016/j.jaad.2005.06.015
Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21:984–99.
pubmed: 25796139 pmcid: 4744804 doi: 10.1016/j.bbmt.2015.02.025
Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129:30–7.
pubmed: 27821503 pmcid: 5216262 doi: 10.1182/blood-2016-07-686642
Mitchell SA, Jacobsohn D, Thormann Powers KE, Carpenter PA, Flowers ME, Cowen EW, et al. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant. 2011;17:1619–29.
pubmed: 21536143 pmcid: 3158826 doi: 10.1016/j.bbmt.2011.04.002
El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, et al. Improved treatment-related mortality and overall survival of patients with grade IV acute GVHD in the modern years. Biol Blood Marrow Transplant. 2016;22:910–8.
pubmed: 26748160 doi: 10.1016/j.bbmt.2015.12.024
Hahn T, McCarthy PL Jr., Hassebroek A, Bredeson C, Gajewski JL, Hale GA, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31:2437–49.
pubmed: 23715573 pmcid: 3691359 doi: 10.1200/JCO.2012.46.6193
Garnett C, Apperley JF, Pavlu J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4:366–78.
pubmed: 24319572 pmcid: 3854558 doi: 10.1177/2040620713489842
Carpenter PA, Kitko CL, Elad S, Flowers ME, Gea-Banacloche JC, Halter JP, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015;21:1167–87.
pubmed: 25838185 pmcid: 4821166 doi: 10.1016/j.bbmt.2015.03.024
Mukherjee A, Ekinci E, Scholoff A, Obi G, Vu N, Carrum G, et al. Voriconazole photosensitivity causes apparent graft-versus-host disease exacerbation. Bone Marrow Transplant. 2019;54:323–5.
pubmed: 30087464 doi: 10.1038/s41409-018-0285-3
El-Jawahri A. What else do I need to worry about when treating graft-versus-host disease? Hematology Am Soc Hematol Educ Program. 2021;2021:655–61.
pubmed: 34889363 pmcid: 8791094 doi: 10.1182/hematology.2021000302
Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30–45.
pubmed: 22533831 doi: 10.1111/j.1365-2141.2012.09129.x
Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl. 1989;151:7–10. discussion 47-52.
Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16:1611–28.
pubmed: 20601036 doi: 10.1016/j.bbmt.2010.06.015
Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol. 2001;137:1202–6.
pubmed: 11559218 doi: 10.1001/archderm.137.9.1202
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445–55.
pubmed: 36260792 doi: 10.1056/NEJMoa2118828
Markova A, Pan A, Dusza S, Chowdhury A, Kukoyi O, Parales M-A, et al. Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease. Blood. 2021;138:3915.
doi: 10.1182/blood-2021-144743
MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387–94.
pubmed: 12171485 doi: 10.1053/bbmt.2002.v8.pm12171485
Mielcarek M, Furlong T, Storer BE, Green ML, McDonald GB, Carpenter PA, et al. Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica. 2015;100:842–8.
pubmed: 25682602 pmcid: 4450631 doi: 10.3324/haematol.2014.118471
Pidala J, Onstad L, Martin PJ, Hamilton BK, Cutler C, Kitko CL, et al. Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. Blood Adv. 2021;5:4549–59.
pubmed: 34535015 pmcid: 8759136 doi: 10.1182/bloodadvances.2021005286
Hings IM, Filipovich AH, Miller WJ, Blazar BL, McGlave PB, Ramsay NK, et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation. 1993;56:577–80.
pubmed: 8212152 doi: 10.1097/00007890-199309000-00016
Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, et al. Steroid treatment of acute graft-versus-host disease grade I: a randomized trial. Haematologica. 2017;102:2125–33.
pubmed: 28971905 pmcid: 5709112 doi: 10.3324/haematol.2017.171157
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800–10.
pubmed: 32320566 doi: 10.1056/NEJMoa1917635
Khandelwal P, Teusink-Cross A, Davies SM, Nelson AS, Dandoy CE, El-Bietar J, et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2017;23:1122–7.
pubmed: 28344057 doi: 10.1016/j.bbmt.2017.03.029
Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48–51.
pubmed: 12070007 doi: 10.1182/blood.V100.1.48
De Jong CN, Saes L, Klerk CPW, Van der Klift M, Cornelissen JJ, Broers AEC. Etanercept for steroid-refractory acute graft-versus-host disease: a single center experience. PLoS ONE. 2017;12:e0187184.
pubmed: 29073260 pmcid: 5658201 doi: 10.1371/journal.pone.0187184
Ma CKK, Garcia-Cadenas I, Fox ML, Ai S, Nivison-Smith I, Milliken ST, et al. Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis. Bone Marrow Transplant. 2018;53:1478–82.
pubmed: 29795434 doi: 10.1038/s41409-018-0215-4
Park JH, Lee HJ, Kim SR, Song GW, Lee SK, Park SY, et al. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Korean J Intern Med. 2014;29:630–6.
pubmed: 25228839 pmcid: 4164727 doi: 10.3904/kjim.2014.29.5.630
Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol. 2006;135:382–5.
pubmed: 16984386 doi: 10.1111/j.1365-2141.2006.06321.x
Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95:83–9.
pubmed: 10607689 doi: 10.1182/blood.V95.1.83
Garcia-Cadenas I, Valcarcel D, Martino R, Pinana JL, Novelli S, Esquirol A, et al. Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19:435–9.
pubmed: 23178634 doi: 10.1016/j.bbmt.2012.11.012
Chakupurakal G, Garcia-Marquez MA, Shimabukuro-Vornhagen A, Theurich S, Holtick U, Hallek M, et al. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody. Eur J Haematol. 2016;97:121–7.
pubmed: 26492560 doi: 10.1111/ejh.12691
Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L, Gonzalez-Llano O, Gutierrez-Aguirre H, Cantu-Rodriguez O, et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:10–5.
pubmed: 18158956 doi: 10.1016/j.bbmt.2007.08.052
Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, et al. A prospective study of alemtuzumab as a second-line agent for steroid-refractory acute graft-versus-host disease in pediatric and young adult allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:2220–5.
pubmed: 27664325 pmcid: 5683393 doi: 10.1016/j.bbmt.2016.09.016
Graziani F, Van Lint MT, Dominietto A, Raiola AM, Di Grazia C, Lamparelli T, et al. Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. Haematologica. 2002;87:973–8.
pubmed: 12217810
Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, et al. Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT. Bone Marrow Transplant. 2017;52:252–7.
pubmed: 27869808 doi: 10.1038/bmt.2016.247
Nishimoto M, Nakamae H, Koh H, Nakamae M, Hirose A, Hayashi Y, et al. Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin. Exp Hematol. 2015;43:177–9.
pubmed: 25584866 doi: 10.1016/j.exphem.2014.11.008
Alam N, Atenafu EG, Tse G, Viswabandya A, Gupta V, Kim D, et al. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease. Clin Transplant. 2013;27:930–7.
pubmed: 24304375 doi: 10.1111/ctr.12268
Bolanos-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005;23:2661–8.
pubmed: 15837980 doi: 10.1200/JCO.2005.06.130
Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, et al. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant. 2018;53:315–25.
pubmed: 29269797 doi: 10.1038/s41409-017-0034-z
Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol. 2004;73:56–61.
pubmed: 15182339 doi: 10.1111/j.1600-0609.2004.00247.x
Nassar A, Elgohary G, Elhassan T, Nurgat Z, Mohamed SY, Aljurf M. Methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. J Transplant. 2014;2014:980301.
pubmed: 25405023 pmcid: 4227326 doi: 10.1155/2014/980301
Gergoudis SC, DeFilipp Z, Ozbek U, Sandhu KS, Etra AM, Choe HK, et al. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with alpha-1-antitrypsin. Blood Adv. 2020;4:6098–105.
pubmed: 33351103 pmcid: 7756981 doi: 10.1182/bloodadvances.2020003336
Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, et al. alpha(1)-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018;131:1372–9.
pubmed: 29437593 pmcid: 5865235 doi: 10.1182/blood-2017-11-815746
Marcondes AM, Hockenbery D, Lesnikova M, Dinarello CA, Woolfrey A, Gernsheimer T, et al. Response of Steroid-Refractory Acute GVHD to alpha1-Antitrypsin. Biol Blood Marrow Transplant. 2016;22:1596–601.
pubmed: 27223109 doi: 10.1016/j.bbmt.2016.05.011
Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:465–71.
pubmed: 15931635 doi: 10.1016/j.bbmt.2005.03.002
Fan S, Huo WX, Yang Y, Shen MZ, Mo XD. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis. Front Immunol. 2022;13:954268.
pubmed: 35990629 pmcid: 9386528 doi: 10.3389/fimmu.2022.954268
Chen YB, Perales MA, Li S, Kempner M, Reynolds C, Brown J, et al. Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood. 2017;129:3256–61.
pubmed: 28473406 doi: 10.1182/blood-2017-03-772210
Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273–7.
pubmed: 17549053 doi: 10.1038/sj.bmt.1705725
Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010;95:1935–42.
pubmed: 20663943 pmcid: 2966917 doi: 10.3324/haematol.2010.026104
Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756–62.
pubmed: 16551963 pmcid: 1895490 doi: 10.1182/blood-2006-01-0233
Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243–50.
pubmed: 28924018 pmcid: 6033048 doi: 10.1182/blood-2017-07-793786
Pai CC, Chen M, Mirsoian A, Grossenbacher SK, Tellez J, Ames E, et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood. 2014;124:1677–88.
pubmed: 25009225 pmcid: 4155274 doi: 10.1182/blood-2014-02-554279
Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP 3rd, Armand P, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1737–43.
pubmed: 25017765 pmcid: 4465759 doi: 10.1016/j.bbmt.2014.06.040
Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114:709–18.
pubmed: 19403889 doi: 10.1182/blood-2009-02-204156
de Masson A, Bouaziz JD, Peffault de Latour R, Wittnebel S, Ribaud P, Rubio MT, et al. Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood. 2012;120:5089–90.
pubmed: 23243159 doi: 10.1182/blood-2012-09-453928
Baird K, Comis LE, Joe GO, Steinberg SM, Hakim FT, Rose JJ, et al. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:1083–90.
pubmed: 25771402 pmcid: 4425991 doi: 10.1016/j.bbmt.2015.03.006
Pusic I, Rettig MP, DiPersio JF, Bauer S, McFarland K, Gale RP, et al. Phase-1/-2 study of pomalidomide in chronic GvHD. Bone Marrow Transplant. 2016;51:612–4.
pubmed: 26657832 doi: 10.1038/bmt.2015.298
Curtis LM, Ostojic A, Venzon DJ, Holtzman NG, Pirsl F, Kuzmina ZJ, et al. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. Blood. 2021;137:896–907.
pubmed: 32976576 pmcid: 7918188 doi: 10.1182/blood.2020006892
Parker PM, Chao N, Nademanee A, O’Donnell MR, Schmidt GM, Snyder DS, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86:3604–9.
pubmed: 7579470 doi: 10.1182/blood.V86.9.3604.bloodjournal8693604
Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2000;26:865–9.
pubmed: 11081386 doi: 10.1038/sj.bmt.1702626
Holtzman NG, Im A, Ostojic A, Curtis LM, Parsons-Wandell L, Nashed J, et al. Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): preliminary analysis results of a phase 1/2 study. Blood. 2020;136:1.
doi: 10.1182/blood-2020-140392
Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055–66.
pubmed: 22129252 pmcid: 3727432 doi: 10.1056/NEJMoa1108188
Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128:130–7.
pubmed: 27073224 pmcid: 4937358 doi: 10.1182/blood-2016-02-702852
Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021;138:2278–89.
pubmed: 34265047 pmcid: 8641099 doi: 10.1182/blood.2021012021
Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135:1739–49.
pubmed: 32160294 pmcid: 7229262 doi: 10.1182/blood.2020004823
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021;385:228–38.
pubmed: 34260836 doi: 10.1056/NEJMoa2033122
Duan MH, Cao XX, Chang L, Zhou DB. Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms. Hematology. 2021;26:460–4.
pubmed: 34184610 doi: 10.1080/16078454.2021.1945234
Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93:339–47.
pubmed: 29150886 doi: 10.1002/ajh.24976
Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369:197–8.
pubmed: 23841743 doi: 10.1056/NEJMc1302135
Chin KK, Kim HT, Inyang EA, Ho V, Koreth J, Romee R, et al. Ibrutinib in steroid-refractory chronic graft-versus-host disease, a single-center experience. Transplant Cell Ther. 2021;27:990.e1–e7.
pubmed: 34481113 doi: 10.1016/j.jtct.2021.08.017
Carpenter PA, Kang HJ, Yoo KH, Zecca M, Cho B, Lucchini G, et al. Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the phase 1/2 iMAGINE Study. Transplant Cell Ther. 2022;28:771.e1–e10.
pubmed: 36044977 doi: 10.1016/j.jtct.2022.08.021
Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56–63.
pubmed: 30878129 doi: 10.1016/j.critrevonc.2019.02.001
Przepiorka D, Le RQ, Ionan A, Li RJ, Wang YH, Gudi R, et al. FDA approval summary: belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy. Clin Cancer Res. 2022;28:2488–92.
pubmed: 35135839 pmcid: 9197942 doi: 10.1158/1078-0432.CCR-21-4176
Zhou X, Jin N, Wang F, Chen B. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease. Cancer Cell Int. 2020;20:114.
pubmed: 32280306 pmcid: 7137413 doi: 10.1186/s12935-020-01193-z
Bader P, Kuci Z, Bakhtiar S, Basu O, Bug G, Dennis M, et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transplant. 2018;53:852–62.
pubmed: 29379171 pmcid: 6039391 doi: 10.1038/s41409-018-0102-z
Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013;163:501–9.
pubmed: 23992039 doi: 10.1111/bjh.12545
Dotoli GM, De Santis GC, Orellana MD, de Lima Prata K, Caruso SR, Fernandes TR, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:859–62.
pubmed: 28287644 doi: 10.1038/bmt.2017.35
Fernandez-Maqueda C, Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, Sanchez R, Bueno JL, et al. Mesenchymal stromal cells for steroid-refractory acute GvHD. Bone Marrow Transplant. 2017;52:1577–9.
pubmed: 28783146 doi: 10.1038/bmt.2017.177
Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant. 2014;20:375–81.
pubmed: 24321746 doi: 10.1016/j.bbmt.2013.11.033
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.
pubmed: 18468541 doi: 10.1016/S0140-6736(08)60690-X
Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013;98:206–13.
pubmed: 23860964 doi: 10.1007/s12185-013-1399-4
Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103:243–50.
pubmed: 26608364 doi: 10.1007/s12185-015-1915-9
Perez-Simon JA, Lopez-Villar O, Andreu EJ, Rifon J, Muntion S, Diez Campelo M, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica. 2011;96:1072–6.
pubmed: 21393326 pmcid: 3128230 doi: 10.3324/haematol.2010.038356
Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3:225–38.
pubmed: 23997985 pmcid: 3755522
Salmenniemi U, Itala-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transplant. 2017;52:606–8.
pubmed: 27941780 doi: 10.1038/bmt.2016.317
Sanchez-Guijo F, Caballero-Velazquez T, Lopez-Villar O, Redondo A, Parody R, Martinez C, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1580–5.
pubmed: 24952358 doi: 10.1016/j.bbmt.2014.06.015
Servais S, Baron F, Lechanteur C, Seidel L, Selleslag D, Maertens J, et al. Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. Oncotarget. 2018;9:20590–604.
pubmed: 29755674 pmcid: 5945536 doi: 10.18632/oncotarget.25020
von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N, et al. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome. Stem Cells. 2016;34:357–66.
doi: 10.1002/stem.2224
Boberg E, von Bahr L, Afram G, Lindstrom C, Ljungman P, Heldring N, et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: a phase II study. Stem Cells Transl Med. 2020;9:1190–202.
pubmed: 32573983 pmcid: 7519760 doi: 10.1002/sctm.20-0099
Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, et al. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Res Ther. 2022;13:93.
pubmed: 35246235 pmcid: 8895864 doi: 10.1186/s13287-022-02751-0
Drexler B, Buser A, Infanti L, Stehle G, Halter J, Holbro A. Extracorporeal photopheresis in graft-versus-host disease. Transfus Med Hemother. 2020;47:214–25.
pubmed: 32595426 pmcid: 7315199 doi: 10.1159/000508169
Sakellari I, Gavriilaki E, Batsis I, Mallouri D, Panteliadou AK, Lazaridou A, et al. Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: prospective single-center study. J Clin Apher. 2018;33:654–60.
pubmed: 30394564 doi: 10.1002/jca.21660
Nygaard M, Karlsmark T, Andersen NS, Schjodt IM, Petersen SL, Friis LS, et al. Extracorporeal photopheresis is a valuable treatment option in steroid-refractory or steroid-dependent acute graft versus host disease-experience with three different approaches. Bone Marrow Transplant. 2019;54:150–4.
pubmed: 29907805 doi: 10.1038/s41409-018-0262-x
Niittyvuopio R, Juvonen E, Heiskanen J, Lindstrom V, Nihtinen A, Sahlstedt L, et al. Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience. Transfusion. 2018;58:1973–9.
pubmed: 29707788 doi: 10.1111/trf.14649
Malagola M, Cancelli V, Skert C, Leali PF, Ferrari E, Tiburzi A, et al. Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: an Italian multicentric retrospective analysis on 94 patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo. Transplantation. 2016;100:e147–55.
pubmed: 27861297 doi: 10.1097/TP.0000000000001466
Hautmann AH, Wolff D, Hahn J, Edinger M, Schirmer N, Ammer J, et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. Bone Marrow Transplant. 2013;48:439–45.
pubmed: 22922407 doi: 10.1038/bmt.2012.156
Hackstein H, Amoros JJ, Bein G, Woessmann W. Successful use of miniphotopheresis for the treatment of graft-versus-host disease. Transfusion. 2014;54:2022–7.
pubmed: 24666366 doi: 10.1111/trf.12596
Cid J, Carbasse G, Suarez-Lledo M, Moreno DF, Martinez C, Gutierrez-Garcia G, et al. Efficacy and safety of one-day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft-versus-host disease. Transfusion. 2019;59:2636–42.
pubmed: 31135994 doi: 10.1111/trf.15384
Jagasia M, Greinix H, Robin M, Das-Gupta E, Jacobs R, Savani BN, et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant. 2013;19:1129–33.
pubmed: 23623892 doi: 10.1016/j.bbmt.2013.04.018
Malik MI, Litzow M, Hogan W, Patnaik M, Murad MH, Prokop LJ, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res. 2014;49:100–6.
pubmed: 25025011 pmcid: 4090330 doi: 10.5045/br.2014.49.2.100
Ballester-Sanchez R, Navarro-Mira MA, de Unamuno-Bustos B, Pujol-Marco C, Sanz-Caballer J, Botella-Estrada R. The role of phototherapy in cutaneous chronic graft-vs-host disease: a retrospective study and review of the literature. Actas Dermosifiliogr. 2015;106:651–7.
pubmed: 26032871
Bonanomi S, Balduzzi A, Tagliabue A, Biagi E, Rovelli A, Corti P, et al. Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease. Bone Marrow Transplant. 2001;28:631–2.
pubmed: 11607781 doi: 10.1038/sj.bmt.1703151
Eppinger T, Ehninger G, Steinert M, Niethammer D, Dopfer R. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation. 1990;50:807–11.
pubmed: 2238056 doi: 10.1097/00007890-199011000-00013
Ghoreschi K, Thomas P, Penovici M, Ullmann J, Sander CA, Ledderose G, et al. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. Eur J Dermatol. 2008;18:667–70.
pubmed: 18955201
Hoffner MV, Carrizosa Esquivel A, Pulpillo Ruiz A, Herrera Saval A, Conejo-Mir J, Camacho FM. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy. J Drugs Dermatol. 2009;8:1027–9.
pubmed: 19894371
Jampel RM, Farmer ER, Vogelsang GB, Wingard J, Santos GW, Morison WL. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol. 1991;127:1673–8.
pubmed: 1952971 doi: 10.1001/archderm.1991.01680100073007
Leiter U, Kaskel P, Krahn G, Gottlober P, Bunjes D, Peter RU, et al. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. Photodermatol Photoimmunol Photomed. 2002;18:183–90.
pubmed: 12390673 doi: 10.1034/j.1600-0781.2002.00719.x
Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant. 1996;17:1061–7.
pubmed: 8807115
Schlaak M, Schwind S, Wetzig T, Maschke J, Treudler R, Basara N, et al. UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant. 2010;45:1741–8.
pubmed: 20921941 doi: 10.1038/bmt.2010.230
Feldstein JV, Bolanos-Meade J, Anders VL, Abuav R. Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. J Am Acad Dermatol. 2011;65:733–8.
pubmed: 21616558 pmcid: 3653316 doi: 10.1016/j.jaad.2010.08.006
George L, Peter D, Chopra M, George B, Abraham A, Mathews V, et al. Efficacy of narrow band UVB in the treatment of cutaneous GvHD: an Indian experience. Bone Marrow Transplant. 2016;51:988–90.
pubmed: 26901707 doi: 10.1038/bmt.2016.13
Grundmann-Kollmann M, Martin H, Ludwig R, Klein S, Boehncke WH, Hoelzer D, et al. Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation. 2002;74:1631–4.
pubmed: 12490799 doi: 10.1097/00007890-200212150-00023
Snyder AN, Wine Lee L, Jaroscak JJ, Donahoo LB, Hudspeth M. Outcomes using narrowband UVB phototherapy for acute cutaneous graft versus host disease in pediatric allogeneic hematopoietic stem cell transplant recipients. J Pediatr Hematol Oncol. 2021;43:e151–3.
pubmed: 33315852 doi: 10.1097/MPH.0000000000001945
Brazzelli V, Grasso V, Muzio F, Moggio E, Zecca M, Locatelli F, et al. Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. Br J Dermatol. 2010;162:404–9.
pubmed: 19903177 doi: 10.1111/j.1365-2133.2009.09503.x
Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22:1179–83.
pubmed: 9894721 doi: 10.1038/sj.bmt.1701460

Auteurs

Junshik Hong (J)

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
ORCID: 0000-0002-7829-397X

Johnathan Fraebel (J)

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Yenny Yang (Y)

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Eric Tkacyk (E)

Veterans Affairs Tennessee Valley Health Care, Nashville, TN, USA.
Department of Dermatology, Vanderbilt University Medical Center, Nashville, TN, USA.
ORCID: 0000-0002-2850-4740

Carrie Kitko (C)

Monroe Carell Jr Children's Hospital, Vanderbilt Division of Pediatric Hematology-Oncology, Nashville, TN, USA.
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

Tae Kon Kim (TK)

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. tae.k.kim@vumc.org.
Veterans Affairs Tennessee Valley Health Care, Nashville, TN, USA. tae.k.kim@vumc.org.
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. tae.k.kim@vumc.org.
Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA. tae.k.kim@vumc.org.
ORCID: 0000-0002-5182-3870

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Understanding and treatment of cutaneous...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Understanding and treatment of cutaneous...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Understanding and treatment of cutaneous...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › Understanding and treatment of cutaneous...
questionsmedicales.fr › Système tégumentaire › Peau › Understanding and treatment of cutaneous...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation de tissu › Transplantation de moelle osseuse › Understanding and treatment of cutaneous...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Understanding and treatment of cutaneous...